ISREC – Swiss Institute for Experimental Cancer Research

The protein behind immunotherapy resistance

Published:18.11.22 — Scientists at EPFL, Ludwig Institute of Cancer Research, and CHUV have identified a key protein that helps tumors evade attacks by the immune system, contributing to poor responses to immunotherapy in the clinic.

Can Aztekin receives Branco Weiss Fellowship

Published:06.09.22 — The Branco Weiss Fellowship-Society in Science has selected ELISIR Scholar Dr Can Aztekin at EPFL as one of its new Fellows in 2022.

Breakthrough study of hormone “crosstalk” in breast cancer

Published:16.06.22 — Scientists led by EPFL have successfully engrafted breast cancer cells on mice, allowing them to study in vivo the cross-talk between the estrogen and progesterone receptors that hampers hormone therapies. Their findings suggest that endocrine therapy may need to be personalized, and that abrogating progesterone receptor expression can be a therapeutic option.